The initial success of Sildenafil undeniably revolutionized the drug landscape, but placing funds in companies heavily reliant on off-patent versions presents a challenging picture. Despite early earnings were significant, the expiration of patents and the appearance of less expensive alternatives have eroded sales. Therefore, a thorough assessment